These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26347243)

  • 1. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.
    Suttels V; Florence E; Leys J; Vekemans M; Van den Ende J; Vlieghe E; Kenyon C
    J Med Case Rep; 2015 Sep; 9():190. PubMed ID: 26347243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
    Godinho R; Bugnon S; Gracin T; Tataw J
    BMC Nephrol; 2019 Feb; 20(1):69. PubMed ID: 30808332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient.
    Wassner C; Maiti S; Kodroff K; Cohen H
    J Int Assoc Provid AIDS Care; 2017; 16(6):535-539. PubMed ID: 28895486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Adams JL; Byrne D; Pepe R; Gray A; Baxter JD
    Antivir Ther; 2016; 21(2):175-80. PubMed ID: 26308882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of Stribild in the Southeast United States.
    Derrick CB; Lu ZK; Caulder CR; Hester EK; Wagner TD; Bookstaver PB
    J Int Assoc Provid AIDS Care; 2016 Sep; 15(5):432-9. PubMed ID: 27225853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
    Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
    Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
    Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
    Squillace N; Ricci E; Quirino T; Gori A; Bandera A; Carenzi L; De Socio GV; Orofino G; Martinelli C; Madeddu G; Rusconi S; Maggi P; Celesia BM; Cordier L; Vichi F; Calza L; Falasca K; Di Biagio A; Pellicanò GF; Bonfanti P;
    PLoS One; 2017; 12(6):e0179254. PubMed ID: 28632758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
    BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.
    White K; Kulkarni R; Miller MD
    J Antimicrob Chemother; 2015 Sep; 70(9):2632-8. PubMed ID: 26108607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
    Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
    Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
    Raffe S; Fisher M
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):427-35. PubMed ID: 25553805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
    Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
    Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.